Top Industry Leaders in the Americas Gastrointestinal Drugs Market
Latest Americas Gastrointestinal Drugs Companies Updates:
AbbVie Inc. (US) Secured FDA approval for Skyrizi™ (risankizumab) injection for the treatment of moderate-to-severe Crohn's disease, expanding its portfolio of biologic GI drugs.
Takeda Pharmaceutical Company Ltd. (Japan) Received FDA approval for Entyvio® (vedolizumab) as a maintenance therapy for adult patients with moderate-to-severe ulcerative colitis, offering a longer-term treatment option.
Johnson & Johnson (US) Announced positive Phase 3 data for Stelara® (ustekinumab) in the treatment of moderate-to-severe ulcerative colitis, potentially expanding its market reach.
AstraZeneca PLC (UK) Partnered with Regeneron Pharmaceuticals for the co-development and commercialization of their investigational IL-23 p19 antibody, REGN3500, for the treatment of IBD, leveraging strengths in research and development.
Evelo Biosciences Inc. (US) Received FDA Breakthrough Therapy designation for its investigational microbiome therapy, evobr007, for the treatment of ulcerative colitis, highlighting the potential of innovative approaches in GI therapeutics.
List of Americas Gastrointestinal Drugs Key companies in the market:
- AbbVie Inc. (US)
- AstraZeneca (UK)
- Valeant (US)
- Abbott Laboratories(US)
- Allergan Plc (US)
- Bayer AG (Germany)
- Janssen Biotech Inc. (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Eisai Co., Ltd. (Japan)
- Valeant Pharmaceuticals (US)
- Sanofi (France)
